Tue. Jun 6th, 2023

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions, adds New U.S. Patent to Portfolio

By

Feb 25, 2023

RADNOR – NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911.
This patent, issued… | February 23, 2023

You missed

Global IPR

[Sponsored] PatSeer Announces the Launch of a New AI-driven Semantic Search Built on a Custom-TrainedGPT Model

Jun 6, 2023

Global IPR

SpicyIP Weekly Review (May 29- June 3)

Jun 5, 2023

Global IPR

National Mission on Quantum Technologies and Applications (NM-QTA) – III

Jun 4, 2023

Global IPR

National Mission on Quantum Technologies and Applications (NM-QTA) – II

Jun 3, 2023

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions, adds New U.S. Patent to Portfolio

By

Related Post

[Sponsored] PatSeer Announces the Launch of a New AI-driven Semantic Search Built on a Custom-TrainedGPT Model

SpicyIP Weekly Review (May 29- June 3)

National Mission on Quantum Technologies and Applications (NM-QTA) – III

You missed

[Sponsored] PatSeer Announces the Launch of a New AI-driven Semantic Search Built on a Custom-TrainedGPT Model

SpicyIP Weekly Review (May 29- June 3)

National Mission on Quantum Technologies and Applications (NM-QTA) – III

National Mission on Quantum Technologies and Applications (NM-QTA) – II